OLYMPIA
Clinical Trial Program
A randomised, double-blind, parallel group, placebo-controlled multi-centre, phase III study to assess the efficacy and safety of olaparib vs placebo as adjuvant treatment in patients with germline BRCA 1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotheraphy.
Phase III
Status
Recruiting
Tumour subtype:
HR+, TNBC
Scenario
Adjuvant
SPONSOR
PRINCIPAL INVESTIGATORS
Andrew Tutt, MD, PhD (Integrated Cancer Centre Guy's Hospital King's College, London)
Sites
CENTRO ONCOLOGICO MD ANDERSON INTERNACIONAL ESPAÑA, HOSPITAL CLÍNICO UNIV. SANTIAGO DE COMPOSTELA, HOSPITAL CLÍNICO UNIVERSITARIO DE VALENCIA, HOSPITAL QUIRON DEXEUS (Instituto Oncológico Dr. Rosell), HOSPITAL SON ESPASES, HOSPITAL UNIVERSITARI SANT JOAN DE REUS, HOSPITAL UNIVERSITARI VALL D’HEBRON, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, ICO GIRONA (HOSPITAL DR. JOSEP TRUETA), ICO HOSPITALET (DURAN I REYNALS), HOSPITAL BEATRIZ ANGELO, HOSPITAL CUF DESCOBERTAS, HOSPITAL DA LUZ, IPO LISBOA (INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL, EPE), IPO PORTO (INSTITUTO PORTUGUÊS DE ONCOLOGIA DE PORTO FRANCISCO GENTIL, EPE )
